|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0021467,
umls-concept:C0021469,
umls-concept:C0334227,
umls-concept:C1280500,
umls-concept:C1414805,
umls-concept:C1514873,
umls-concept:C1546857,
umls-concept:C1556066,
umls-concept:C1619636,
umls-concept:C2698651,
umls-concept:C2916795
|
|
pubmed:issue |
23
|
|
pubmed:dateCreated |
2009-12-2
|
|
pubmed:abstractText |
A significant fraction of HER2-overexpressing breast cancers exhibit resistance to the HER2 antibody trastuzumab. Hyperactivity of the phosphatidylinositol 3-kinase (PI3K)/AKT pathway confers trastuzumab resistance, and mammalian target of rapamycin (mTOR) is a major downstream effector of PI3K/AKT. Therefore, we examined whether mTOR inhibitors synergize with trastuzumab.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, Humanized,
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/HER2 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Intracellular Signaling Peptides...,
http://linkedlifedata.com/resource/pubmed/chemical/MTOR protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Phosphatidylinositol 3-Kinases,
http://linkedlifedata.com/resource/pubmed/chemical/Protein-Serine-Threonine Kinases,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor, erbB-2,
http://linkedlifedata.com/resource/pubmed/chemical/TOR Serine-Threonine Kinases,
http://linkedlifedata.com/resource/pubmed/chemical/mTOR protein, mouse,
http://linkedlifedata.com/resource/pubmed/chemical/trastuzumab
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
pubmed-author:ArteagaCarlos LCL,
pubmed-author:CookRebecca SRS,
pubmed-author:DuggerTeresa CTC,
pubmed-author:ForbesJames TJT,
pubmed-author:KennedyJ PhillipJP,
pubmed-author:LindsleyCraig WCW,
pubmed-author:ManningH CharlesHC,
pubmed-author:MillerTodd WTW,
pubmed-author:NarasannaArchanaA,
pubmed-author:OlivaresMaria GMG,
pubmed-author:SanchezVioletaV,
pubmed-author:ShahChirayuC,
pubmed-author:WyattShelby KSK,
pubmed-author:de Matos GranjaNaraN
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
15
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
7266-76
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:19934303-Animals,
pubmed-meshheading:19934303-Antibodies, Monoclonal,
pubmed-meshheading:19934303-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:19934303-Antineoplastic Agents,
pubmed-meshheading:19934303-Breast Neoplasms,
pubmed-meshheading:19934303-Cell Line, Tumor,
pubmed-meshheading:19934303-Cell Proliferation,
pubmed-meshheading:19934303-Drug Resistance, Neoplasm,
pubmed-meshheading:19934303-Female,
pubmed-meshheading:19934303-Humans,
pubmed-meshheading:19934303-Intracellular Signaling Peptides and Proteins,
pubmed-meshheading:19934303-Mice,
pubmed-meshheading:19934303-Mice, SCID,
pubmed-meshheading:19934303-Neoplasms,
pubmed-meshheading:19934303-Phosphatidylinositol 3-Kinases,
pubmed-meshheading:19934303-Phosphorylation,
pubmed-meshheading:19934303-Protein-Serine-Threonine Kinases,
pubmed-meshheading:19934303-Receptor, erbB-2,
pubmed-meshheading:19934303-TOR Serine-Threonine Kinases
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Inhibition of mammalian target of rapamycin is required for optimal antitumor effect of HER2 inhibitors against HER2-overexpressing cancer cells.
|
|
pubmed:affiliation |
Department of Medicine, Vanderbilt University, Nashville, Tennessee, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Research Support, N.I.H., Extramural
|
